Safety and efficacy of a new solution, XyloCore, for peritoneal dialysis

The primary objective of this study is to demonstrate the non-inferiority of XyloCore compared to the standard treatment of glucose PD solutions, with regards to the weekly Kt/Vurea. The study will also measure: 1. Changes from the baseline values of LDL, HDL and total cholesterol, serum triglycerides, HbA1c (glycated haemoglobin), and insulin 2. Changes from the baseline values of hemoglobin and EPO requirements (medication used to manage anemia in patients on dialysis) 3. Patients’ subjective assessment of fatigue (Chalder Fatigue Scale) 4. Peritoneal ultrafiltration 5. Diuresis (24 hours urinary volume) 6. Residual kidney function (measured as the arithmetic mean of urinary urea and creatinine clearance)